United States· US:84141-025_20832f43-4967-4ced-ac62-989dbe66c40f
REDEMPLO
A medicinal product containing plozasiran, registered in United States by Arrowhead Pharmaceuticals, Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- PLOZASIRAN
- Manufacturer
- Arrowhead Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- August 23, 2026
Packs & prices · 2
- ndc1184141025011 SYRINGE, GLASS in 1 CARTON (84141-025-01) / 1 mL in 1 SYRINGE, GLASS
- ndc1184141-025-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Plozasiran in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainREDEMPLO 25 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAArrowhead Pharmaceuticals Ireland Limited
- NetherlandsRedemplo 25 mg oplossing voor injectie in een voorgevulde spuitArrowhead Pharmaceuticals Ireland Limited
- PolandRedemploArrowhead Pharmaceuticals Ireland Limited
- SwedenRedemplo 25 mg Injektionsvätska, lösning i förfylld sprutaArrowhead Pharmaceuticals Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Redemplo
- Liechtenstein · Redemplo
- Norway · Redemplo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7c38cba9-bc6f-4acb-a9ba-e3562eef7fb9 GET /v1/drugs/7c38cba9-bc6f-4acb-a9ba-e3562eef7fb9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "25",
"substance": "PLOZASIRAN",
"productndc": "84141-025",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/.5mL",
"application_number": "NDA219947",
"marketing_category": "NDA"
}See everything about plozasiran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.